0001209191-21-012207.txt : 20210218 0001209191-21-012207.hdr.sgml : 20210218 20210218210034 ACCESSION NUMBER: 0001209191-21-012207 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210216 FILED AS OF DATE: 20210218 DATE AS OF CHANGE: 20210218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aurentz Vincent CENTRAL INDEX KEY: 0001657494 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 21651726 BUSINESS ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 453-7200 MAIL ADDRESS: STREET 1: C/O ARENA PHARMACEUTICALS, INC. STREET 2: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: Vincent Aurentz DATE OF NAME CHANGE: 20151103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-16 0 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001657494 Aurentz Vincent C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 0 1 0 0 Executive VP and CBO Common Stock 2021-02-16 4 M 0 2500 14.60 A 29500 D Common Stock 2021-02-16 4 M 0 24 35.60 A 29524 D Common Stock 2021-02-16 4 S 0 2524 85.00 D 27000 D Employee Stock Option (right to buy) 14.60 2021-02-16 4 M 0 2500 0.00 D 2024-02-13 Common Stock 2500 77000 D Employee Stock Option (right to buy) 35.60 2021-02-16 4 M 0 24 0.00 D 2025-01-19 Common Stock 24 94976 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. /s/ Andrew J. Cronauer, as Attorney-in-Fact 2021-02-18